Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Forbes has recognized Gilead as one of America's Best Employers for Diversity. The company's commitment to inclusion and diversity is highlighted, reflecting positive feedback from employees and the community. Gilead Sciences, a biopharmaceutical company, aims to innovate medicines for unmet medical needs globally.
Gilead Sciences, Inc. (Nasdaq: GILD) executives will be speaking at several upcoming investor conferences, showcasing the company's commitment to advancing innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The live webcasts and replays will be available on the company's investors page. Gilead operates globally with headquarters in Foster City, California.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.